• Ljelja Muaremoska Kanzoska University Clinic for Pediatrics, Neurology Department, Skopje, North Macedonia.
  • Filip Duma University Clinic for Pediatrics, Neurology Department, Skopje, North Macedonia.
  • Valentina Dukovska University Clinic for Pediatrics, Neurology Department, Skopje, North Macedonia.
  • Natalija Angelkova Acibadem Sistina Hospital, Skopje, North Macedonia.
  • Shpresa Muaremoska Useini SHGO “Mother Teresa” – Chair, Skopje, North Macedonia.
  • Mevmed Djaferi Hospital Dr. Ruse Boshkoski – Rostushe, North Macedonia.
  • Ana Karandjinska Radevska GH “Kumanovo” – Kumanovo, North Macedonia.


LAMA2 associated muscular dystrophy, genetic testing of clinically relevant genes, genetic counseling.


Introduction: LAMA2 Associated Muscular Dystrophy (LAMA2-RD) is one of the most common forms of congenital muscular dystrophy worldwide. Mutations in the LAMA2 gene affect the production of the α2 subunit of lamin-211 (merosine) and result in partial or complete deficiency of lamin-211. Inheritance is usually autosomal recessive.

Case report: We present a patient who is dual heterozygous for two pathogenic variants in the LAMA2 gene, as demonstrated by targeted resection of 4800 clinically significant genes. c.4474dupT, p. (Tyr1492LeufsTer11), inherited from the mother and c.7732C> T, p. (Arg2578Ter), inherited from the father. With this genotype the patient is confirmed autosomal recessive disease, LAMA2-RD.
Variant c.4474dupT, p. (Tyr1492LeufsTer11), in exon 31 of the LAMA2 gene, is a change that has not been reported in the literature.

Conclusion: Genetic confirmation of the diagnosis is important for genetic counseling, prenatal diagnosis for each subsequent pregnancy in the family because the risk of an affected child is 25%. 


Allamand, V., & Guicheney, P. (2002). Merosin-deficient congenital muscular dystrophy, autosomal recessive (MDC1A, MIM#156225, LAMA2 gene coding for alpha2 chain of laminin). Eur J Hum Genet. , pp. 91-94.

Bertini, E., D"Amico, A., Guilandi, F., & Petrini, S. (2011, Dec). Congenital Muscular Dystrophies: A Brief Review. Semin Pediatr Neurol.; , 18(4), pp. 277–288.

Dimova, I., & Kremensky, I. (2018). LAMA2 Congenital Muscle Dystrophy: A Novel Pathogenic Mutation in Bulgarian Patient. Case Reports in Genetics.

Geranmayeh, F., & al, e. (2010). Genotype-phenotype correlation in a large population of muscular dystrophy patients with LAMA2 mutations. Neuromuscul Disord., pp. 241-250.

Jayakody, H. e. (2020, sept). Cobblestone Malformation in LAMA2 Congenital Muscular Dystrophy (MDC1A). Journal of Neuropathology &Experimental Neurology September 2020, Pages 998–1010, 79(9), pp. 998-1010.

Marques, J. e. (2014). Atypical phenotype in two patients with LAMA2 mutations, neuromuscular disorders.

Menezes, M., & al, e. (2014). The extracellular matrix protein laminin α2 regulates the maturation and function of the blood-brain barrier. J Neurosci., pp. 15260–80.

Mercuri, E., & al, e. (1999). Cognitive abilities in children with congenital muscular dystrophy: correlation with brain MRI and merosin status. Neuromuscul Disord., pp. 383-387.

Muaremoska Kanzoska, L. e. (2019). Lissencephaly-new pathogenic variantof PAFAH 1B1 Gene associated with autosomal dominant inheritance and refractory epilepsy - case report. Physioacta, 13(2), pp. 75-81.

Natera‐de Benito, D. e. (2020, may). Epilepsy in LAMA2‐related muscular dystrophy: An electro‐clinico‐radiological characterization. Epilepsia Oficial Journal of international league against epilepsy, 61(5), pp. 971-983.

Oliveira, J., & al, e. (2018). LAMA2 gene mutation update: toward a more comprehensive picture of the laminin-α2 variome and its related phenotypes. Hum Mutat., pp. 1314-1337.

Oliveira, J., & al, e. (2020). LAMA2 Muscular Dystrophy. Retrieved from GeneReviews® [Internet]:

Pegoraro, E., & al, e. (1998). Laminin alpha2 muscular dystrophy: genotype/phenotype studies of 22 patients. Neurology., 51, pp. 101-110.

Saredi, S., & al, e. (2019). Exome sequencing detects compound heterozygous nonsense LAMA2 mutations in two siblings with atypical phenotype and nearly normal brain MRI. Neuromuscul Disord., pp. 376-380.

Sarkozy, A., Foley, A. R., Zambon, A. A., Bönnemann, G. C., & Muntoni, F. (2020). LAMA2-Related Dystrophies: Clinical Phenotypes, Disease Biomarkers, and Clinical Trial Readiness. Front. Mol. Neurosci.,. Doi:

Scrivener, T., Ross, S., Street, N., Webster, R., & De Lima, J. (2014, Apr). A case series of general anesthesia in children with laminin alpha2 (merosin)-deficient congenital muscular dystrophy. Paediatr Anaesth, 24(4), pp. 464-465.

Shukry, M., Guruli, Z., & Rhamadyani, U. (2006, apr). Suspected malignant hyperthermia in a child with laminin alpha2 (merosin) deficiency in the absence of a triggering agent. Paediatr Anaesth, 16(4), pp. 462-465.

Tezak, Z., & al, e. (2003). nical and molecular study in congenital muscular dystrophy with partial laminin alpha 2 (LAMA2) deficiency. Hum Mutat., pp. 103-111.

Turner, C., Mein, R., Sharpe, S., & Love, D. (2015, Dec). Merosin-deficient congenital muscular dystrophy: A novel homozygous mutation in the laminin-2 gene. J Clin Neurosci, 22(12), pp. 1983-1985.

Vigliano, P., Dassi, P., Di Blasi, C., Mora, M., & Jarre, L. (2009). LAMA2 stop-codon mutation: merosin-deficient congenital muscular dystrophy with occipital polymicrogyria, epilepsy and psychomotor regression. Eur J Paediatr Neurol., pp. 72-76.

Xiong, H., & al, e. (2015). Genotype/phenotype analysis in Chinese laminin-α2 deficient congenital muscular dystrophy patients. Clin. Genet., pp. 233-243. Doi: 10.1111/cge.12366.




How to Cite

Kanzoska, L. M., Duma, F., Dukovska, V., Angelkova, N., Useini, S. M., Djaferi, M., & Radevska, A. K. (2021). LAMA2–ASSOCIATED CONGENITAL MUSCULAR DYSTROPHY: CASE REPORT. International Journal of Medicine & Healthcare, 6(1), 51–58. Retrieved from